全文获取类型
收费全文 | 9563篇 |
免费 | 653篇 |
国内免费 | 55篇 |
专业分类
耳鼻咽喉 | 108篇 |
儿科学 | 192篇 |
妇产科学 | 161篇 |
基础医学 | 1204篇 |
口腔科学 | 146篇 |
临床医学 | 1179篇 |
内科学 | 2648篇 |
皮肤病学 | 132篇 |
神经病学 | 816篇 |
特种医学 | 337篇 |
外国民族医学 | 2篇 |
外科学 | 1247篇 |
综合类 | 88篇 |
现状与发展 | 1篇 |
一般理论 | 6篇 |
预防医学 | 628篇 |
眼科学 | 126篇 |
药学 | 532篇 |
中国医学 | 2篇 |
肿瘤学 | 716篇 |
出版年
2023年 | 44篇 |
2022年 | 68篇 |
2021年 | 174篇 |
2020年 | 116篇 |
2019年 | 177篇 |
2018年 | 235篇 |
2017年 | 152篇 |
2016年 | 174篇 |
2015年 | 210篇 |
2014年 | 276篇 |
2013年 | 382篇 |
2012年 | 636篇 |
2011年 | 647篇 |
2010年 | 398篇 |
2009年 | 378篇 |
2008年 | 591篇 |
2007年 | 662篇 |
2006年 | 549篇 |
2005年 | 591篇 |
2004年 | 597篇 |
2003年 | 502篇 |
2002年 | 481篇 |
2001年 | 132篇 |
2000年 | 129篇 |
1999年 | 117篇 |
1998年 | 117篇 |
1997年 | 95篇 |
1996年 | 78篇 |
1995年 | 82篇 |
1994年 | 72篇 |
1993年 | 50篇 |
1992年 | 117篇 |
1991年 | 83篇 |
1990年 | 84篇 |
1989年 | 75篇 |
1988年 | 69篇 |
1987年 | 83篇 |
1986年 | 59篇 |
1985年 | 72篇 |
1984年 | 56篇 |
1983年 | 64篇 |
1982年 | 33篇 |
1980年 | 43篇 |
1979年 | 38篇 |
1978年 | 41篇 |
1977年 | 47篇 |
1974年 | 38篇 |
1973年 | 30篇 |
1972年 | 34篇 |
1971年 | 42篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
121.
Analysis of the p21 gene in gliomas 总被引:4,自引:0,他引:4
Li You-Jun Hoang-Xuan Khê Hoang-Xuan Khê Zhou Xiao-Ping Sanson Marc Mokhtari Karima Faillot Thierry Cornu Philippe Poisson Michel Thomas Gilles Hamelin Richard 《Journal of neuro-oncology》1998,40(2):107-111
The p21 gene encodes a cyclin dependent kinase inhibitor protein (p21) which has a tumor suppressive activity in a variety of tumor cell lines. Since, the p21 gene is up-regulated by the p53 tumor suppressor gene, which is frequently mutated in gliomas, acting therefore in the same control pathway, it constitutes a good candidate gene to be also inactivated in these tumors. To test this hypothesis, DNAs from 81 gliomas (48 glioblastomas, 11 anaplastic astrocytomas, 10 low-grade astrocytomas, 12 oligodendrogliomas and mixed gliomas), were investigated for mutations in the p21 coding sequence by denaturant gradient gel electrophoresis followed by sequencing. All these tumors have been previously screened for p53 mutations. Three different DNA variants were identified on codon 31 (17 cases), 27 (1 case) and 117 (1 case) and shown to be also present in matching constitutional DNA, suggesting they were polymorphisms. None of the tumors demonstrated a somatic mutation. No significant correlation between the presence of a p21 variant and the p53 mutation tumor status was observed. In conclusion, mutation in the p21 gene unlikely contributes to the development of gliomas. 相似文献
122.
Fran?ois L'Hériteau Corinne Alberti Yves Cohen Gilles Troché Pierre Moine Jean-Fran?ois Timsit 《Infection control and hospital epidemiology》2005,26(1):13-20
OBJECTIVES: To evaluate nosocomial infection (NI) surveillance strategies in French ICUs and to identify similar patterns defining subsets within which comparisons can be made. DESIGN: A questionnaire was sent to all French ICUs, and a random sample of nonresponders was interviewed. PARTICIPANTS: Three hundred ninety-five responder ICUs (69%) in France. RESULTS: In 282 ICUs (71%), a dedicated ICU staff member was responsible for infection control activities. The microbiology laboratory was usually in the hospital (90%) and computerized (94%) but issued regular hospital microbiology records in only 48% of cases. Patients receiving mechanical ventilation, central venous catheterization, and urinary catheterization were 90%, 79%, and 60%, respectively. Patients were screened for carriage of multidrug-resistant bacteria on admission and during the stay in 70% and 60% of ICUs, respectively, most often targeting MRSA. Quantitative cultures were used to diagnose ventilator-associated pneumonia (VAP) in 90% of ICUs, including distal specimens in 80% and bronchoscopy specimens in 60%. Quantitative central venous catheter (CVC)-segment cultures were used in 70% of ICUs. All CVCs were cultured routinely in 53% of the ICUs. Despite wide variations in infection control and surveillance strategies, multiple correspondence analysis identified 13 key points (4 structural variables and 9 variables concerning the diagnosis of VAP, the surveillance and diagnosis of catheter-related and urinary tract infections, and the mode of screening of MRSA carriers) that categorize the variability of French ICUs' approaches to NIs. CONCLUSION: This study revealed profound differences in NI surveillance strategies across ICUs, indicating a need for caution when using NI surveillance data for comparisons and benchmarking. 相似文献
123.
Federle M Chezmar J Rubin DL Weinreb J Freeny P Schmiedl UP Brown JJ Borrello JA Lee JK Semelka RC Mattrey R Dachman AH Saini S Harms SE Mitchell DG Anderson MW Halford HH Bennett WF Young SW Rifkin M Gay SB Ballerini R Sherwin PF Robison RO 《Journal of magnetic resonance imaging : JMRI》2000,12(5):689-701
The efficacy of contrast-enhanced magnetic resonance imaging (MRI) for detecting and characterizing, or excluding, hepatic masses was assessed in 404 patients, following the intravenous administration of mangafodipir trisodium (MnDPDP) injection, a hepatic MRI contrast agent. An initial contrast-enhanced computed tomography (CT) examination was followed by unenhanced MRI, injection of MnDPDP (5 micromol/kg IV), and enhanced MRI at 15 minutes post injection. Agreement of the radiologic diagnoses with the patients' final diagnoses was higher for enhanced MRI and for the combined unenhanced and enhanced MRI evaluations than for unenhanced MRI alone or enhanced CT using the clinical diagnosis as the gold standard. Mangafodipir-enhanced MRI uniquely provided additional diagnostic information in 48% of the patients, and patient management was consequently altered in 6% of the patients. MnDPDP-enhanced MRI was comparable or superior to unenhanced MRI and enhanced CT for the detection, classification, and diagnosis of focal liver lesions in patients with known or suspected focal liver disease. 相似文献
124.
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. 总被引:11,自引:0,他引:11
Andre Goy Anas Younes Peter McLaughlin Barbara Pro Jorge E Romaguera Frederick Hagemeister Luis Fayad Nam H Dang Felipe Samaniego Michael Wang Kristine Broglio Barry Samuels Frederic Gilles Andreas H Sarris Susan Hart Elizabeth Trehu David Schenkein Fernando Cabanillas Alma M Rodriguez 《Journal of clinical oncology》2005,23(4):667-675
PURPOSE: Evaluate efficacy and toxicity of bortezomib in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. PATIENTS AND METHODS: Patients were stratified, based on preclinical data, into arm A (mantle-cell lymphoma) or arm B (other B-cell lymphomas) without limitation in number of prior therapies. Bortezomib was administered as an intravenous push (1.5 mg/m2) on days 1, 4, 8, and 11 every 21 days for a maximum of six cycles. RESULTS: Sixty patients with a median number of prior therapies of 3.5 (range, one to 12 therapies) were enrolled; 33 patients were in arm A and 27 were in arm B, including 12 diffuse large B-cell lymphomas, five follicular lymphomas (FL), three transformed FLs, four small lymphocytic lymphomas (SLL), two Waldenstrom's macroglobulinemias (WM), and one marginal zone lymphoma. In arm A, 12 of 29 assessable patients responded (six complete responses [CR] and six partial responses [PR]) for an overall response rate (ORR) of 41% (95% CI, 24% to 61%), and a median time to progression not reached yet, with a median follow-up of 9.3 months (range, 1.7 to 24 months). In arm B, four of 21 assessable patients responded (one SLL patient had a CR, one FL patient had a CR unconfirmed, one diffuse large B-cell lymphoma patient had a PR, and one WM patient had a PR) for an ORR of 19% (95% CI, 5% to 42%). Grade 3 toxicity included thrombocytopenia (47%), gastrointestinal (20%), fatigue (13%), neutropenia (10%), and peripheral neuropathy (5%). Grade 4 toxicity occurred in nine patients (15%), and three deaths from progression of disease occurred within 30 days of withdrawal from study. CONCLUSION: Bortezomib showed promising activity in relapsed mantle-cell lymphoma and encouraging results in other B-cell lymphomas. Future studies will explore bortezomib in combination with other cytotoxic or biologic agents. 相似文献
125.
126.
Diego Iacono Peter Zandi Myron Gross William R. Markesbery Olga Pletnikova Gay Rudow Juan C. Troncoso 《Oncotarget》2015,6(16):14082-14091
Asymptomatic Alzheimer''s disease (ASYMAD) subjects are individuals characterized by preserved cognition before death despite substantial AD pathology at autopsy. ASYMAD subjects show comparable levels of AD pathology, i.e. β-amyloid neuritic plaques (Aβ-NP) and tau-neurofibrillary tangles (NFT), to those observed in mild cognitive impairment (MCI) and some definite AD cases. Previous clinicopathologic studies on ASYMAD subjects have shown specific phenomena of hypertrophy in the cell bodies, nuclei, and nucleoli of hippocampal pyramidal neurons and other cerebral areas. Since it is well established that the allele APOε4 is a major genetic risk factor for AD, we examined whether specific alleles of APOE could be associated with the different clinical outcomes between ASYMAD and MCI subjects despite equivalent AD pathology. A total of 523 brains from the Nun Study were screened for this investigation. The results showed higher APOε2 frequency (p < 0.001) in ASYMAD (19.2%) vs. MCI (0%) and vs. AD (4.7%). Furthermore, higher education in ASYMAD vs. MCI and AD (p < 0.05) was found. These novel autopsy-verified findings support the hypothesis of the beneficial effect of APOε2 and education, both which seem to act as contributing factors in delaying or forestalling the clinical manifestations of AD despite consistent levels of AD pathology. 相似文献
127.
The increasing occurrence of antibiotic-resistant bacteria combined with regulatory pressure and consumer demands for foods produced without antibiotics has caused the agricultural industry to restrict its practice of using antibiotic growth promoters (AGP) in food animals. The poultry industry is not immune to this trend, and has been actively seeking natural alternatives to AGP that will improve the health and growth performance of commercial poultry flocks. Bacillus probiotics have been gaining in popularity in recent years as an AGP alternative because of their health-promoting benefits and ability to survive the harsh manufacturing conditions of chicken feed production. This review provides an overview of several modes of action of some Bacillus direct-fed microbials as probiotics. Among the benefits of these direct-fed microbials are their production of naturally synthesized antimicrobial peptides, gut flora modulation to promote beneficial microbiota along the gastrointestinal tract, and various immunological and gut morphological alterations. The modes of action for increased performance are not well defined, and growth promotion is not equal across all Bacillus species or within strains. Appropriate screening and characterization of Bacillus isolates prior to commercialization are necessary to maximize poultry growth to meet the ultimate goal of eliminating AGP usage in animal husbandry. 相似文献
128.
129.
130.